PDCD1 and non-small cell lung carcinoma: In 2015, the first PD-1 inhibitor (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for previously treated advanced or metastatic squamous and non-squamous NSCLC [12, 13].